Paul P. Carbone Comprehensive Cancer Center, University of Wisconsin, Madison, 53706, USA.
Cancer Chemother Pharmacol. 2010 Jan;65(2):399-401. doi: 10.1007/s00280-009-1118-2. Epub 2009 Sep 16.
We report a case of bevacizumab (BEV)-induced thrombocytopenia in a 36-year-old woman treated with BEV as a single-agent for a recurrent high-grade glioma. The thrombocytopenia was both reversible and reproducible on multiple treatment cycles. The patient has improved clinically and by brain MR imaging with single-agent BEV for approximately 7 months to date. She did not have bleeding or thromboembolic complications. Treatment delays have been 1-2 weeks relative to a conventional plan of treatment, i.e., 10 mg/kg every 2 weeks. This is a rare complication that has not been previously reported.
我们报告了一例贝伐单抗（BEV）诱导的血小板减少症病例，该患者为 36 岁女性，因复发性高级别胶质瘤接受 BEV 单药治疗。血小板减少症在多次治疗周期中均是可逆和可重复的。迄今为止，该患者接受 BEV 单药治疗约 7 个月，临床状况和脑部磁共振成像（MR）均得到改善。她没有出血或血栓栓塞并发症。与传统治疗计划（即每 2 周 10mg/kg）相比，治疗延迟了 1-2 周。这是一种以前未报道过的罕见并发症。
